Literature DB >> 32060549

Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.

Shaheena Parween1,2, Mónica Fernández-Cancio3, Sara Benito-Sanz4, Núria Camats3, Maria Natalia Rojas Velazquez1,2,5, Juan-Pedro López-Siguero6, Sameer S Udhane1,2, Norio Kagawa7, Christa E Flück1,2, Laura Audí3, Amit V Pandey1,2.   

Abstract

CONTEXT: Mutations in cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We report a novel R550W mutation in POR identified in a 46,XX patient with signs of aromatase deficiency.
OBJECTIVE: Analysis of aromatase deficiency from the R550W mutation in POR. DESIGN, SETTING, AND PATIENT: Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C > T/p.R550W in POR. Wild-type and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children's Hospital, Bern, Switzerland. MAIN OUTCOME MEASURE AND
RESULTS: POR-R550W showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity, and CYP17A1 as well as CYP21A2 activities were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed.
CONCLUSIONS: Pathological effects due to POR-R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CY19A1; CYP17A1; CYP21A2; POR; PORD; congenital adrenal hyperplasia

Mesh:

Substances:

Year:  2020        PMID: 32060549     DOI: 10.1210/clinem/dgaa076

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Inhibition of placental CYP19A1 activity remains as a valid hypothesis for 46,XX virilization in P450 oxidoreductase deficiency.

Authors:  Christa E Flück; Shaheena Parween; Maria Natalia Rojas Velazquez; Amit V Pandey
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-23       Impact factor: 11.205

Review 2.  Congenital adrenal hyperplasia, disorders of sex development, and infertility in patients with POR gene pathogenic variants: a systematic review of the literature.

Authors:  C Gusmano; R Cannarella; A Crafa; F Barbagallo; S La Vignera; R A Condorelli; A E Calogero
Journal:  J Endocrinol Invest       Date:  2022-07-17       Impact factor: 5.467

3.  Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.

Authors:  Valiyaparambil Pavithran Praveen; Asmahane Ladjouze; Kay-Sara Sauter; Annie Pulickal; Efstathios Katharopoulos; Mafalda Trippel; Aurel Perren; Amit V Pandey; Christa E Flück
Journal:  J Endocr Soc       Date:  2020-03-10

4.  Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.

Authors:  Tomasz M Wróbel; Oksana Rogova; Katyayani Sharma; Maria Natalia Rojas Velazquez; Amit V Pandey; Flemming Steen Jørgensen; Frederic S Arendrup; Kasper L Andersen; Fredrik Björkling
Journal:  Biomolecules       Date:  2022-01-20

5.  Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels.

Authors:  Maria Natalia Rojas Velazquez; Mathias Noebauer; Amit V Pandey
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.